Predictive value of cellular immune response in cervical cancer | RJME
Recommend Documents
Feb 6, 2017 - were divided two groups: group 1, 0-7 admissions per year and group 2, >7 .... echocardiography (EPIQ 7 Ultrasound System, PHILIPS, HEIDE,.
A Genetic DNA Cassette as Candidate Vaccine against Urinary. Tract Infection. Ronak BAKHTIARI 1, 2, *Shahin AHMADIAN 1, Jalil FALLAH MEHRABADI 3. 1.
Feb 9, 2017 - influence risk of developing cervical cancer, as well as progression and survival among ... database and HuGE navigator was conducted [46].
Jun 16, 2017 - 4 Department of Genomic Medicine, The University of Texas MD Anderson .... able cervical cancer data sets, namely the Cancer Genome Atlas.
exposure leading to mesothelioma or reflux oesophagitis leading to ...... intratumoural IDO expression is due to eosinophil infiltration rather than ..... The future of cancer immunotherapy? ..... Int J Oral and Maxillofacial Surg 2007; 36(6): 541-4.
Typhi has been reported to express iron-uptake systems characterized by ..... Sharma-Rishi, P., Sharma, B. K., Sharma, S., Rawal, I. J., Saxena, S. M.,. Seghal, R.
The mutated p53155 peptide-specific CTL clone in an HLA-Cw*0702 restriction was established and ... expressed in autologous lung cancer cells exist in the tumor tissue. ... primary tumor tissue of the same patient together with humoral ..... and cell
Jun 3, 2007 - empower stronger tumor-specific responses, which have led in recent years to a .... LMP-specific CTL responses in HLA A2/Kb transgenic mice,.
Jackson Laboratory) mice were used for this study. All mice had ad ...... Morin N, Owolabi SA, Harty MW, Papa EF, Tracy TF Jr, Shaw SK, Kim M,. Saab CY.
Nov 1, 2009 - Despite recent advances in the immune mechanisms of cervical cancer (CC), the relapse still remains an actual issue and recognition of.
Romanian Journal of Morphology and Embryology 2009, 50(4):651–655
ORIGINAL PAPER Predictive value of cellular immune response in cervical cancer E. ANCUŢA1), CODRINA ANCUŢA2), F. ZUGUN-ELOAE2,3), CRISTINA IORDACHE2), RODICA CHIRIEAC2), E. CARASEVICI2,3) 1) 2) 3)
Research Department, “Cuza-Vodă” Hospital, Iassy
“Grigore T. Popa” University of Medicine and Pharmacy, Iassy
Immunopathology and Genetics Laboratory, “Sf. Spiridon” Hospital, Iassy
Abstract
Despite recent advances in the immune mechanisms of cervical cancer (CC), the relapse still remains an actual issue and recognition of new predictive biomarkers is essential. Aim: The purpose of this retrospective study was to investigate possible differences in the primary, in situ, cellular immune response between cervical carcinoma with and without relapse. Material and Methods: Paraffin-embedded tissue samples from 61 consecutive women with CC (34 with and 27 without relapse) were immunostained for CD3, CD20 and CD45 cells. Immune cell profile densities were further assessed, assigning scores between 0 and 3: “0” meaning the absence of inflammatory infiltrate, “1+” low, “2+” intense and “3+” intense infiltrate with lymphoid follicles. Statistical analysis was performed in SPSS–13 software, p
